



Specialty Pharmaceuticals Service

About HIRC's Specialty Pharmaceuticals Service

The *Specialty Pharmaceuticals Service* presents managed care trends in specialty pharmaceutical benefit plan design, patient cost-sharing and enrollment, out-of-pocket limits, formularies, specialty pharmacy, physician reimbursement, and utilization management tactics.

Health Plan Management of Multiple Sclerosis

Health plans are using a variety of tools and approaches to manage the utilization and cost of multiple sclerosis (MS) specialty therapies. HIRC's new report, *Multiple Sclerosis Management — National and Regional Case Studies*, examines the various ways that three health plans manage MS. A second case study examines Teva's *Shared Solutions* program in detail through the eyes of a regional health plan partner.

HIRC's multiple sclerosis case studies offer important insights into how payers are managing MS medications through use of cost-sharing, formulary controls, specialty pharmacy, and case management programs.

Key Finding

Case Study Highlights MS Management at Three Health Plans

HIRC's multiple sclerosis case studies offer important insights into how payers are managing MS medications. HIRC interviewed pharmacy and medical directors at two large national health plans and one regional health plan to better understand how they are managing MS medications and their expectations for the future evolution of management controls. This case study highlights the various approaches these health plans use (as shown in the box to the right). HIRC also provides key implications and recommendations for pharmaceutical manufacturers in the following areas:

- Patient cost-sharing
- Formulary access
- Contracting

MS Case Study Highlights:

- Patient cost-sharing
- Formulary design and enforcement
- Utilization management usage & criteria
- Specialty pharmacy usage
- Pharmaceutical contracting
- Pharmaceutical company support

Additionally, this report includes a case study highlighting Teva's *Shared Solutions* case management and patient education program. This program has a 90% enrollment rate for Copaxone patients.

The *Multiple Sclerosis Management — National and Regional Case Studies* report is part of the *Specialty Pharmaceuticals Service*. For information on how to subscribe to the *Specialty Pharmaceuticals Service* please contact:

Karen Lucas, Research Director | 760.452.6352 | kluca@hirc.com



303 Potrero Street #42-305
Santa Cruz, CA 95060

www.hirc.com